3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid has been researched along with gyki 52466 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meldrum, BS; Smith, SE | 1 |
| Craggs, M; Dürmüller, N; Meldrum, BS | 1 |
| al-Zubaidy, Z; Chapman, AG; Meldrum, BS | 1 |
3 other study(ies) available for 3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid and gyki 52466
| Article | Year |
|---|---|
Receptor site specificity for the acute effects of beta-N-methylamino-alanine in mice.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amino Acids, Diamino; Animals; Anti-Anxiety Agents; Anticonvulsants; Behavior, Animal; Benzodiazepines; Cyanobacteria Toxins; Glutamine; Ibotenic Acid; Injections, Intraventricular; Kainic Acid; Kinetics; Male; Mice; N-Methylaspartate; Organophosphorus Compounds; Piperazines; Receptors, Drug; Receptors, N-Methyl-D-Aspartate | 1990 |
The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Behavior, Animal; Benzodiazepines; Electric Stimulation; Kindling, Neurologic; Male; Piperazines; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Seizures | 1994 |
Aniracetam reverses the anticonvulsant action of NBQX and GYKI 52466 in DBA/2 mice.
Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Dose-Response Relationship, Drug; Mice; Mice, Inbred DBA; Piperazines; Pyrrolidinones; Quinoxalines; Receptors, N-Methyl-D-Aspartate; Seizures | 1993 |